Pharma companies are under pressure to improve the quality and efficiency of their content. Learn how to select your first SCA use case.
By treating content as data, rather than documents, most of the problems inherent in monolithic documents are remedied.
If we can’t eliminate silos, we need to embrace silos. We need to find ways to maximize the effectiveness of multiple silos while enhancing the user experience.
To automate content development, pharmaceutical companies must move to structured content authoring.
In pharma, some digital marketing teams have embraced multi-channel publishing as a way to meet regulatory requirements.
Because labeling is global and requires localization, pharma companies gain even more benefit from content reuse.
Legacy tools and processes no longer support the business objectives for pharma. The only way to meet the growing demands for more content, faster, is to adopt a structured content ecosystem.
To be successful, we need to get everyone on board with a change. Learn how to persuade people who are totally against change, including what stance to take and how to avoid getting pulled in emotionally.
There is no such thing as a perfect structure because it is going to change over time. With new products and services should come new content types. And new content types often require new structures.
The first thing to decide about special statements is how you will use each category. What type of information goes into a note? A caution? A warning? What really is the difference between a caution and a warning? Most companies that I work with have not defined caution versus warning,